Receptor group

Opioid receptors

4 related receptors and the ligands measured at several of them.

Binding affinity (Kᵢ)

13 ligands measured at two or more members, human values in nM, strongest first. Select a value for its assay and source.

View
Ligandδ-opioid receptorκ-opioid receptorμ-opioid receptorNociceptin/ORL1 receptor
Buprenorphine
Hydromorphonenot measured
Morphinenot measured
Fentanylnot measured
Methadonenot measured
7-Hydroxymitragyninenot measured
Mitragyninenot measured
Hydrocodonenot measured
Oxycodonenot measurednot measured
Salvinorin Anot measured
Codeinenot measurednot measured
Psilocinnot measured
Ibogainenot measurednot measured
Oxymorphonenot measurednot measurednot measured
Tapentadolnot measurednot measurednot measured
Pethidinenot measurednot measurednot measured
Tramadolnot measurednot measurednot measured
Buprenorphine at δ-opioid: Kᵢ 4.5 nM, Toll et al. 1998Buprenorphine at κ-opioid: Kᵢ 0.11 nM, other reports differ, Huang et al. 2001Buprenorphine at μ-opioid: Kᵢ 0.22 nM, other reports differ, Volpe et al. 2011Buprenorphine at Nociceptin/ORL1: Kᵢ 285 nM, Huang et al. 2001Hydromorphone at δ-opioid: Kᵢ 38 nM, Wentland et al. 2009Hydromorphone at κ-opioid: Kᵢ 2.8 nM, Wentland et al. 2009Hydromorphone at μ-opioid: Kᵢ 0.37 nM, Volpe et al. 2011Morphine at δ-opioid: Kᵢ 140 nM, Neumeyer et al. 2012Morphine at κ-opioid: Kᵢ 24 nM, Neumeyer et al. 2012Morphine at μ-opioid: Kᵢ 1.2 nM, other reports differ, Volpe et al. 2011Fentanyl at δ-opioid: Kᵢ 153 nM, other reports differ, Toll et al. 1998Fentanyl at κ-opioid: Kᵢ 85 nM, Toll et al. 1998Fentanyl at μ-opioid: Kᵢ 1.3 nM, other reports differ, Volpe et al. 2011Methadone at δ-opioid: Kᵢ 132 nM, Toll et al. 1998Methadone at κ-opioid: Kᵢ 324 nM, Toll et al. 1998Methadone at μ-opioid: Kᵢ 3.4 nM, other reports differ, Volpe et al. 20117-Hydroxymitragynine at δ-opioid: Kᵢ 219 nM, Kruegel et al. 20167-Hydroxymitragynine at κ-opioid: Kᵢ 188 nM, Kruegel et al. 20167-Hydroxymitragynine at μ-opioid: Kᵢ 47 nM, Kruegel et al. 2016Mitragynine at δ-opioid: Kᵢ 6800 nM, Obeng et al. 2021Mitragynine at κ-opioid: Kᵢ 772 nM, Kruegel et al. 2016Mitragynine at μ-opioid: Kᵢ 233 nM, other reports differ, Kruegel et al. 2016Hydrocodone at κ-opioid: Kᵢ 260 nM, Neumeyer et al. 2012Hydrocodone at μ-opioid: Kᵢ 42 nM, other reports differ, Volpe et al. 2011Hydrocodone at δ-opioid: Kᵢ of 10 µM or weakerOxycodone at μ-opioid: Kᵢ 16 nM, Lalovic et al. 2006Oxycodone at κ-opioid: Kᵢ of 10 µM or weakerSalvinorin A at κ-opioid: Kᵢ 16 nM, other reports differ, Roth et al. 2002Salvinorin A at δ-opioid: Kᵢ of 10 µM or weakerSalvinorin A at μ-opioid: Kᵢ of 10 µM or weakerCodeine at μ-opioid: Kᵢ 734 nM, other reports differ, Volpe et al. 2011Codeine at δ-opioid: Kᵢ of 10 µM or weakerPsilocin at κ-opioid: Kᵢ 2000 nM, Jain et al. 2025Psilocin at δ-opioid: Kᵢ of 10 µM or weakerPsilocin at μ-opioid: Kᵢ of 10 µM or weakerIbogaine at κ-opioid: Kᵢ 3680 nM, Maillet et al. 2015Ibogaine at δ-opioid: Kᵢ of 10 µM or weakerOxymorphone at μ-opioid: Kᵢ 0.41 nM, Volpe et al. 2011Tapentadol at μ-opioid: Kᵢ 160 nM, Tzschentke et al. 2007Pethidine at μ-opioid: Kᵢ 450 nM, Volpe et al. 2011Tramadol at μ-opioid: Kᵢ 2400 nM, Gillen et al. 2000δ-opioid receptorδ-opioidκ-opioid receptorκ-opioidμ-opioid receptorμ-opioidNociceptin/ORL1 receptorNociceptin/ORL1Buprenorphine, Kᵢ: δ-opioid 4.5 nM, κ-opioid 0.11 nM, μ-opioid 0.22 nM, Nociceptin/ORL1 285 nMBuprenorphineHydromorphone, Kᵢ: δ-opioid 38 nM, κ-opioid 2.8 nM, μ-opioid 0.37 nMHydromorphoneMorphine, Kᵢ: δ-opioid 140 nM, κ-opioid 24 nM, μ-opioid 1.2 nMMorphineFentanyl, Kᵢ: δ-opioid 153 nM, κ-opioid 85 nM, μ-opioid 1.3 nMFentanylMethadone, Kᵢ: δ-opioid 132 nM, κ-opioid 324 nM, μ-opioid 3.4 nMMethadone7-Hydroxymitragynine, Kᵢ: δ-opioid 219 nM, κ-opioid 188 nM, μ-opioid 47 nM7-HydroxymitragynineMitragynine, Kᵢ: δ-opioid 6800 nM, κ-opioid 772 nM, μ-opioid 233 nMMitragynineHydrocodone, Kᵢ: δ-opioid 10 µM or weaker, κ-opioid 260 nM, μ-opioid 42 nMHydrocodoneOxycodone, Kᵢ: κ-opioid 10 µM or weaker, μ-opioid 16 nMOxycodoneSalvinorin A, Kᵢ: δ-opioid 10 µM or weaker, κ-opioid 16 nM, μ-opioid 10 µM or weakerSalvinorin ACodeine, Kᵢ: δ-opioid 10 µM or weaker, μ-opioid 734 nMCodeinePsilocin, Kᵢ: δ-opioid 10 µM or weaker, κ-opioid 2000 nM, μ-opioid 10 µM or weakerPsilocinIbogaine, Kᵢ: δ-opioid 10 µM or weaker, κ-opioid 3680 nMIbogaineOxymorphone, Kᵢ: μ-opioid 0.41 nMOxymorphoneTapentadol, Kᵢ: μ-opioid 160 nMTapentadolPethidine, Kᵢ: μ-opioid 450 nMPethidineTramadol, Kᵢ: μ-opioid 2400 nMTramadol
stronger weaker other reports differ 10 µM or weaker (when shown)no line not measured or filtered out, not “inactive”

Lines connect each ligand to the members it has a displayed human Kᵢ at. The thicker and darker the line, the stronger the value. A ligand sits close to the members it binds most strongly and between those it binds about equally, so its position is only approximate. Select a ligand or a member to follow its lines, or a line to see its assay and source. The table view lists the same values.

Functional potency (EC₅₀)

5 ligands measured at two or more members, human values in nM, strongest first. Select a value for its assay and source.

View
Ligandδ-opioid receptorκ-opioid receptorμ-opioid receptorNociceptin/ORL1 receptor
Buprenorphinenot measured
Oxymorphonenot measured
Methadonenot measured
Fentanylnot measured
Morphinenot measured
7-Hydroxymitragyninenot measurednot measurednot measured
Salvinorin Anot measurednot measurednot measured
Oxycodonenot measurednot measurednot measured
Tapentadolnot measurednot measurednot measured
Buprenorphine at κ-opioid: EC₅₀ 0.04 nM, Huang et al. 2001Buprenorphine at μ-opioid: EC₅₀ 2.3 nM, other reports differ, Toll et al. 1998Buprenorphine at Nociceptin/ORL1: EC₅₀ 35 nM, Huang et al. 2001Oxymorphone at δ-opioid: EC₅₀ 259 nM, Ben Haddou et al. 2014Oxymorphone at κ-opioid: EC₅₀ 463 nM, Ben Haddou et al. 2014Oxymorphone at μ-opioid: EC₅₀ 4.4 nM, other reports differ, Ben Haddou et al. 2014Methadone at δ-opioid: EC₅₀ 980 nM, Toll et al. 1998Methadone at κ-opioid: EC₅₀ 4943 nM, Toll et al. 1998Methadone at μ-opioid: EC₅₀ 27 nM, Toll et al. 1998Fentanyl at δ-opioid: EC₅₀ 515 nM, Toll et al. 1998Fentanyl at κ-opioid: EC₅₀ 2368 nM, Toll et al. 1998Fentanyl at μ-opioid: EC₅₀ 28 nM, other reports differ, Obeng et al. 2021Morphine at δ-opioid: EC₅₀ 668 nM, Ben Haddou et al. 2014Morphine at κ-opioid: EC₅₀ 710 nM, other reports differ, Ben Haddou et al. 2014Morphine at μ-opioid: EC₅₀ 34 nM, other reports differ, Ben Haddou et al. 20147-Hydroxymitragynine at μ-opioid: EC₅₀ 43 nM, Obeng et al. 2021Salvinorin A at κ-opioid: EC₅₀ 69 nM, other reports differ, Chavkin et al. 2004Oxycodone at μ-opioid: EC₅₀ 343 nM, Lalovic et al. 2006Tapentadol at μ-opioid: EC₅₀ 670 nM, Tzschentke et al. 2007δ-opioid receptorδ-opioidκ-opioid receptorκ-opioidμ-opioid receptorμ-opioidNociceptin/ORL1 receptorNociceptin/ORL1Buprenorphine, EC₅₀: κ-opioid 0.04 nM, μ-opioid 2.3 nM, Nociceptin/ORL1 35 nMBuprenorphineOxymorphone, EC₅₀: δ-opioid 259 nM, κ-opioid 463 nM, μ-opioid 4.4 nMOxymorphoneMethadone, EC₅₀: δ-opioid 980 nM, κ-opioid 4943 nM, μ-opioid 27 nMMethadoneFentanyl, EC₅₀: δ-opioid 515 nM, κ-opioid 2368 nM, μ-opioid 28 nMFentanylMorphine, EC₅₀: δ-opioid 668 nM, κ-opioid 710 nM, μ-opioid 34 nMMorphine7-Hydroxymitragynine, EC₅₀: μ-opioid 43 nM7-HydroxymitragynineSalvinorin A, EC₅₀: κ-opioid 69 nMSalvinorin AOxycodone, EC₅₀: μ-opioid 343 nMOxycodoneTapentadol, EC₅₀: μ-opioid 670 nMTapentadol
stronger weaker other reports differno line not measured or filtered out, not “inactive”

Lines connect each ligand to the members it has a displayed human EC₅₀ at. The thicker and darker the line, the stronger the value. A ligand sits close to the members it binds most strongly and between those it binds about equally, so its position is only approximate. Select a ligand or a member to follow its lines, or a line to see its assay and source. The table view lists the same values.

stronger weaker≥ 10 µM measured, 10 µM or weakerempty not measured* other reports differ† source not traced to the original

Human values only. A cell shows the value displayed on the compound page, from one assay. Values from different assays are not directly interchangeable, and a value does not establish clinical potency or safety.